The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase

Cancer Prevention Research

Volumn 1, Issue 5, 2008, Pages 369-375

  Zakikhani, Mahvash ^a   Dowling, Ryan J O ^a   Sonenberg, Nahum ^b   Pollak, Michael N ^c  

^a Department of Oncology ^*  (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN, HUMAN; CYTOSTATIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; S6 KINASE; SMALL INTERFERING RNA;

ARTICLE; CARCINOMA; CELL PROLIFERATION; CELL STRAIN HT29; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; HUMAN; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; TUMOR CELL CULTURE;

ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; CARCINOMA; CELL PROLIFERATION; COLONIC NEOPLASMS; CYTOSTATIC AGENTS; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HT29 CELLS; HUMANS; MALE; METFORMIN; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RIBOSOMAL PROTEIN S6 KINASES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 61449113987     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0081     Document Type: Article

References (31)

1. Salt I, Celler JW, Hawley SA, et al. AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the α2 isoform. Biochem J 1998;334:177-87.
2. Hardie DG. AMPK and SNF1: snuffing out stress. Cell Metab 2007;6:339-40.
3. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15-25.
4. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinol 2003;144:5179-83.
5. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activatedki nase and regulates apoptosis in response to energy stress. Proc Natl AcadSci U S A 2004;101:3329-35.
6. Bolster DR, Crozier SJ, Kimball SR, Jefferson LS. AMP-activatedpr otein kinase suppresses protein synthesis in rat skeletal muscle through downregulatedmam malian target of rapamycin (mTOR) signaling. J Biol Chem 2002;277:23977-80.
7. Tomas E, Tsao TS, Saha AK, et al. Enhancedmuscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition andAMP-activatedprotein kinase activation. Proc Natl AcadSci U S A 2002;99:16309-13.
8. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization andfatty-acid oxidation by activating AMP-activated protein kinase. Nat Med2002;8:1288-95.
9. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996;87:377-89.
10. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, andmo rtality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
11. Michalakis K, Williams CJ, Mitsiades N, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev 2007; 16:308-13.
12. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-6.
13. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73.
14. Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in longterm tissue culture: effect of insulin. Proc Natl Acad Sci U S A 1976;73:4536-40.
15. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-86.
16. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52.
17. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-86.
18. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin andred ucedrisk of cancer in diabetic patients. BMJ 2005;330:1304-5.
19. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increasedcancer- relatedmortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-8.
20. Kahn BB, Flier JS. Obesity andinsulin resistance. J Clin Invest 2000;106:473-81.
21. Brooks NL, Moore KS, Clark RD, Perfetti MT, Trent CM, Combs TP. Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome? Diabetes Obes Metab 2007;9:246-58.
22. Bray GA. The underlying basis for obesity: relationship to cancer. J Nutr 2002;132:3451-5S.
23. Venkateswaran V, Haddad AQ, Fleshner NE, et al. Association of diet-induced hyperinsulinemia with acceleratedgrow th of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 2007; 99:1793-800.
24. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003;26:2442-50.
25. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006;25:6416-22.
26. Barb D, Neuwirth A, Mantzoros CS, Balk SP. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer 2007;14:995-1005.
27. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-12.
28. Witters LA. The blooming of the French lilac. J Clin Invest 2001;108:1105-7.
29. Cool B, Zinker B, Chiou W, et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes andthe metabolic syndrome. Cell Metab 2006;3:403-16.
30. St Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care 2004;27:2222-8.
31. Jiralerspong S, Giordano SH, Meric-Bernstam F, et al. The effects of metformin on pathologic complete response rates in diabetic breast cancer patients receiving neoadjuvant systemic therapy. J Clin Oncol 2008;26(May 20 suppl); abstract 528.